Table 1 Baseline characteristics of CCPa population according to whether or not they had ICHb during follow-up (01/01/2013–31/12/2017)
Total | Without ICHb | With ICH | p* | |
|---|---|---|---|---|
(N = 3594) | (N = 3433) | (N = 161) | ||
Age | 84.4 [11.5] | 84.3 [11.6] | 86.5 [8.7] | 0.063 |
< 80 years (n 840, 23.4%) | 70.5 [9.5] | 68.1 [11.4] | 72.2 [8.8] | 0.004 |
≥ 80 years (n 2754, 76.6%) | 89.4 [5.5] | 89.3 [5.4] | 89.5 [5.5] | 0.638 |
Sex (women) | 1985 (55.2) | 1895 (55.2) | 90 (55.9) | 0.925 |
Cardiovascular risk factors | ||||
Arterial hypertension | 2707 (75.3) | 2573 (74.9) | 134 (83.2) | 0.017 |
Diabetes | 1510 (42.0) | 1452 (42.3) | 58 (36.0) | 0.115 |
Hypercholesterolemia | 1717 (47.8) | 1628 (47.4) | 89 (55.3) | 0.051 |
Comorbidities | ||||
Cardiovascular disease | 1050 (29.2) | 991 (28.9) | 59 (36.6) | 0.034 |
Ischemic cardiopathy | 634 (17.6) | 601 (17.5) | 33 (20.5) | 0.331 |
Ischemic stroke/Transient ischemic accident | 275 (7.7) | 259 (7.5) | 16 (9.9) | 0.264 |
Peripheral artery disease | 306 (8.5) | 289 (8.4) | 17 (10.6) | 0.342 |
Atrial fibrillation | 998 (27.8) | 947 (27.6) | 51 (31.7) | 0.257 |
Heart failure | 947 (26.3) | 913 (26.6) | 34 (21.1) | 0.123 |
Thromboembolism | 294 (8.2) | 281 (8.2) | 13 (8.1) | 0.960 |
Chronic kidney disease | 893 (24.8) | 857 (25) | 36 (22.4) | 0.455 |
Chronic liver disease | 58 (1.6) | 57 (1.7) | 1 (0.6) | 0.306 |
Other conditioning factors | ||||
Institutionalized | 271 (7.5) | 262 (7.6) | 9 (5.6) | 0.338 |
Record of previous falls | 508 (14.1) | 487 (14.2) | 21 (13.0) | 0.684 |
Cognitive impairment or dementia | 758 (21.1) | 720 (21.0) | 38 (23.6) | 0.424 |
Alcohol consumption | 506 (14.1) | 487 (14.2) | 19 (11.8) | 0.395 |
Falls (background) | 508 (14.3) | 487 (14.1) | 21(13.0) | 0.395 |
Bleeding predisposition | 285 (7.9) | 272 (7.9) | 13 (8.1) | 0.945 |
Clinical data | ||||
Systolic blood pressure (mmHg) | 129.8 [16.2] | 129.6 [16.5] | 132.8 [13.4] | 0.032 |
Glycosylated haemoglobin A1c (%) | 6.6 [2.9] | 6.6 [3.0] | 6.3 [1.4] | 0.247 |
Glomerular filtration rate (mL/min/1.73m2) | 56.8 [23.6] | 56.4 [23.7] | 66.5 [20.9] | 0.093 |
CHA2DS2-VASC score** | 4.6 [1.5] | 4.6 [1.5] | 4.3 [1.5] | 0.669 |
HAS-BLED score | 3.5 [1.1] | 3.3 [0.0] | 3.5 [0.9] | 0.029 |
Barthel index | 70.2 [28.7] | 70.1 [28.9] | 72.4 [23.7] | 0.988 |
Medication | ||||
Oral anticoagulant (VKAc o NOACd) | 1050 (29.2) | 996 (29.0) | 54 (33.5) | 0.217 |
NOACd | 106 (2.9) | 103 (3.0) | 3 (1.9) | 0.405 |
NSAIDe | 2723 (75.8) | 2611 (76.1) | 112 (69.6) | 0.060 |
Antiplatelet drug | 1920 (53.4) | 1817 (52.9) | 103 (64.0) | 0.006 |
Statin | 2006 (55.8) | 1921 (56.0) | 85 (52.8) | 0.430 |
SSRIf | 1252 (34.8) | 1193 (34.8) | 59 (36.6) | 0.622 |
PPIg | 3144 (87.5) | 3008 (87.6) | 136 (84.5) | 0.238 |